[HTML][HTML] A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone …
DJ Khalaf, CM Aviles, AA Azad… - Canadian Urological …, 2018 - ncbi.nlm.nih.gov
DJ Khalaf, CM Aviles, AA Azad, K Sunderland, T Todenhöfer, BJ Eigl, D Finch, L Le, A Atwell…
Canadian Urological Association Journal, 2018•ncbi.nlm.nih.govMethods We identified 197 chemotherapy-naive patients who received abiraterone at six BC
Cancer Agency centres and who had complete information on all six RFs. Study endpoints
were prostate-specific antigen (PSA) response rate (RR), time to PSA progression, time on
treatment, and overall survival (OS). PSA RR and survival outcomes were compared using Χ
2 test and log-rank test. Multivariable Cox proportional hazard analysis was performed to
identify RFs independently associated with OS. Results Patients were classified into good (0 …
Cancer Agency centres and who had complete information on all six RFs. Study endpoints
were prostate-specific antigen (PSA) response rate (RR), time to PSA progression, time on
treatment, and overall survival (OS). PSA RR and survival outcomes were compared using Χ
2 test and log-rank test. Multivariable Cox proportional hazard analysis was performed to
identify RFs independently associated with OS. Results Patients were classified into good (0 …
Methods
We identified 197 chemotherapy-naive patients who received abiraterone at six BC Cancer Agency centres and who had complete information on all six RFs. Study endpoints were prostate-specific antigen (PSA) response rate (RR), time to PSA progression, time on treatment, and overall survival (OS). PSA RR and survival outcomes were compared using Χ 2 test and log-rank test. Multivariable Cox proportional hazard analysis was performed to identify RFs independently associated with OS.
Results
Patients were classified into good (0–1 RFs), intermediate (2–3 RFs), and poor (4–6 RFs) prognostic groups (33%, 52%, and 15%, respectively). For good-, intermediate-, and poor-risk patients, PSA RR (≥ 50% decline) was 60% vs. 42% vs. 40%(p= 0.05); median time to PSA progression was 7.3 vs. 5.3 vs. 5.0 months (p= 0.02); and median OS was 29.4 vs. 13.8 vs. 8.7 months (p< 0.0001).
Conclusions
The six-factor prognostic index model stratifies clinical outcomes in chemotherapy-naive mCRPC patients treated with abiraterone. Identifying patients at risk of poor outcome is important for informing clinical practice and clinical trial design.
ncbi.nlm.nih.gov
